Evaluation of galectin-3 expression in ameloblastoma stromal fibroblasts and its association with recurrence

authors:

avatar Nazanin Mahdavi , avatar Samira Derakhshan , avatar Narges Heidari , *

Koomesh: Vol.24, issue 4; 510-517
published online: August 01, 2022
article type: Research Article
received: April 08, 2021
accepted: January 01, 2022

how to cite: Mahdavi N, Derakhshan S, Heidari N. Evaluation of galectin-3 expression in ameloblastoma stromal fibroblasts and its association with recurrence. koomesh. 2022;24(4):e152760. 

Abstract

Introduction: Ameloblastoma is a benign odontogenic neoplasm with a high risk of recurrence. Ameloblastoma stromal fibroblasts are associated with tumor growth and invasion however, a few studies have evaluated the immunohistochemical characteristics of stromal fibroblasts and their association with recurrence in Ameloblastoma. Galectin-3 (gal-3) is a member of the B-galactoside bonding protein family that is involved in the growth of fibroblasts and their conversion to myofibroblasts. This study aimed to investigate the expression of gal-3 in ameloblastoma stromal fibroblasts and its association with recurrence. Materials and Methods: Forty-eight samples with the diagnosis of ameloblastoma were included in the study. gal-3 expression in stromal fibroblasts was determined using immunohistochemical staining. We also extracted clinical, radiographic, and histological variables from the archived patients;#39 recordings. Results: Thirty-four (70.8%) cases showed nuclear and cytoplasmic expression of gal-3. Four (8.3%) cases revealed only cytoplasmic expression and three cases (6.3%) showed only nuclear positivity for gal-3. We found no statistically significant relationship between tumor recurrence and recurrence-free survival with immunoreactivity for gal-3(Log-rank analysis: P=0.248 and P=0.555, respectively. Cox regression: P=0.272 and P=0.572, respectively). Conclusion: Gal-3 expression was seen in most samples. This protein could be one of the effective proteins in the function of ameloblastoma stromal fibroblasts however, it was not associated with the tumor recurrence and could not be used as a prognostic factor.

References

  • 1.

    Hendra FN, Van Cann EM, Helder MN, Ruslin M, de Visscher JG, Forouzanfar T, et al. Global incidence and profile of ameloblastoma: A systematic review and meta-analysis. Oral Dis 2020; 26: 12-21.https://doi.org/10.1111/odi.13031PMid:30614154.

  • 2.

    Reichart PA, Philipsen HP, Sonner S. Ameloblastoma: biological profile of 3677 cases. Eur J Cancer Part B Oral Oncol 1995; 31b: 86-99.https://doi.org/10.1016/0964-1955(94)00037-5.

  • 3.

    Laborde A, Nicot R, Wojcik T, Ferri J, Raoul G. Ameloblastoma of the jaws: Management and recurrence rate. Eur Ann Otorhinolaryngol Head Neck Dis 2017; 134: 7-11.https://doi.org/10.1016/j.anorl.2016.09.004PMid:27793625.

  • 4.

    Belli E, Rendine G, Mazzone N. Ameloblastoma relapse after 50 years from resection treatment. J Craniofacial Surg 2009; 20: 1146-1149.https://doi.org/10.1097/SCS.0b013e3181abb4c7PMid:19553848.

  • 5.

    Au SW, Li KY, Choi WS, Su YX. Risk factors for recurrence of ameloblastoma: a long-term follow-up retrospective study. Int J Oral Maxillof Surg 2019; 48: 1300-1306.https://doi.org/10.1016/j.ijom.2019.04.008PMid:31084977.

  • 6.

    Hertog D, Bloemena E, Aartman IH, van-der-Waal I. Histopathology of ameloblastoma of the jaws; some critical observations based on a 40 years single institution experience. Med Oral Patol Oral Cir Bucal 2012; 17: e76-82.https://doi.org/10.4317/medoral.18006PMid:22157674 PMCid:PMC3448205.

  • 7.

    Sham E, Leong J, Maher R, Schenberg M, Leung M, Mansour AK. Mandibular ameloblastoma: clinical experience and literature review. ANZ J Surg 2009; 79: 739-744.https://doi.org/10.1111/j.1445-2197.2009.05061.xPMid:19878171.

  • 8.

    Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discover 2019; 18: 99-115.https://doi.org/10.1038/s41573-018-0004-1PMid:30470818.

  • 9.

    Gieniec KA, Butler LM, Worthley DL, Woods SL. Cancer-associated fibroblasts-heroes or villains? Br J Cancer 2019; 121: 293-302.https://doi.org/10.1038/s41416-019-0509-3PMid:31289350 PMCid:PMC6738083.

  • 10.

    Chantravekin Y, Koontongkaew S. Effects of ameloblastoma-associated fibroblasts on the proliferation and invasion of tumor cells. J Cancer Res Ther 2014; 10: 1082-1087.https://doi.org/10.4103/0973-1482.138005PMid:25579558.

  • 11.

    Fuchigami T, Koyama H, Kishida M, Nishizawa Y, Iijima M, Kibe T, et al. Fibroblasts promote the collective invasion of ameloblastoma tumor cells in a 3D coculture model. FEBS Open Bio 2017; 7: 2000-2007.https://doi.org/10.1002/2211-5463.12313PMid:29226086 PMCid:PMC5715246##.

  • 12.

    Kellermann MG, Sobral LM, da Silva SD, Zecchin KG, Graner E, Lopes MA, et al. Myofibroblasts in the stroma of oral squamous cell carcinoma are associated with poor prognosis. Histopathology 2007; 51: 849-853.https://doi.org/10.1111/j.1365-2559.2007.02873.xPMid:18042073.

  • 13.

    Fregnani ER, Sobral LM, Alves FA, Soares FA, Kowalski LP, Coletta RD. Presence of myofibroblasts and expression of matrix metalloproteinase-2 (MMP-2) in ameloblastomas correlate with rupture of the osseous cortical. Pathol Oncol Res 2009; 15: 231-240.https://doi.org/10.1007/s12253-008-9110-4PMid:19096916.

  • 14.

    Takenaka Y, Fukumori T, Raz A. Galectin-3 and metastasis. Glycoconjugate J 2002; 19: 543-549.https://doi.org/10.1023/B:GLYC.0000014084.01324.15PMid:14758078.

  • 15.

    Elola MT, Ferragut F, Mndez-Huergo SP, Croci DO, Bracalente C, Rabinovich GA. Galectins: Multitask signaling molecules linking fibroblast, endothelial and immune cell programs in the tumor microenvironment. Cell Immunol 2018; 333: 34-45.https://doi.org/10.1016/j.cellimm.2018.03.008PMid:29602445.

  • 16.

    Tadokoro T, Ikekita M, Toda T, Ito H, Sato T, Nakatani R, et al. Involvement of Galectin-3 with vascular cell adhesion molecule-1 in growth regulation of mouse BALB/3T3 cells. J Biol Chem 2009; 284: 35556-35563.https://doi.org/10.1074/jbc.M109.063339PMid:19858221 PMCid:PMC2790985##.

  • 17.

    Kim SJ, Lee HW, Gu Kang H, La SH, Choi IJ, Ro JY, et al. Ablation of galectin-3 induces p27(KIP1)-dependent premature senescence without oncogenic stress. Cell Death Differ 2014; 21: 1769-1779.https://doi.org/10.1038/cdd.2014.88PMid:24971481 PMCid:PMC4211374.

  • 18.

    Dvonkov B, Szabo P, Lacina L, Gal P, Uhrova J, Zima T, et al. Human galectins induce conversion of dermal fibroblasts into myofibroblasts and production of extracellular matrix: potential application in tissue engineering and wound repair. Cells Tissues Organs 2011; 194: 469-480.https://doi.org/10.1159/000324864PMid:21494018.

  • 19.

    Farhad M, Rolig AS, Redmond WL. The role of Galectin-3 in modulating tumor growth and immunosuppression within the tumor microenvironment. Oncoimmunology 2018; 7: e1434467.https://doi.org/10.1080/2162402X.2018.1434467PMid:29872573 PMCid:PMC5980349##.

  • 20.

    Ilmer M, Mazurek N, Gilcrease MZ, Byrd JC, Woodward WA, Buchholz TA, et al. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Res 2016; 18: 97.https://doi.org/10.1186/s13058-016-0757-6PMid:27687248 PMCid:PMC5043623.

  • 21.

    Tao L, Jin L, Dechun L, Hongqiang Y, Changhua K, Guijun L. Galectin-3 expression in colorectal cancer and its correlation with clinical pathological characteristics and prognosis. Open Med (Warsaw, Poland) 2017; 12: 226-230.https://doi.org/10.1515/med-2017-0032PMid:28744489 PMCid:PMC5518715.

  • 22.

    Moisa A, Fritz P, Eck A, Wehner HD, Mrdter T, Simon W, et al. Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Res 2007; 27: 2131-2139.

  • 23.

    Than TH, Swethadri GK, Wong J, Ahmad T, Jamil D, Maganlal RK, et al. Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators. Singapore Med J 2008; 49: 333-338.

  • 24.

    Ahlem B, Wided A, Amani L, Nadia Z, Amira A, Faten F. Study of Ki67 and CD10 expression as predictive factors of recurrence of ameloblastoma. Eur Ann Otorhinolaryngol Head Neck Dis 2015; 132: 275-279.https://doi.org/10.1016/j.anorl.2015.08.016PMid:26386615.

  • 25.

    Newlaczyl AU, Yu LG. Galectin-3--a jack-of-all-trades in cancer. Cancer Lett 2011; 313: 123-128.https://doi.org/10.1016/j.canlet.2011.09.003PMid:21974805.

  • 26.

    Califice S, Castronovo V, Bracke M, van den Brle F. Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene 2004; 23: 7527-7536.https://doi.org/10.1038/sj.onc.1207997PMid:15326483.